{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:17:14Z","timestamp":1788797834306,"version":"build-2803163510"},"reference-count":26,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Menarini Hellas"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Although ranolazine has been available for years as a second-line treatment to reduce angina attacks in patients with stable angina pectoris, real-world data on the effectiveness, tolerability, and safety of ranolazine are limited. Methods: A non-interventional, prospective study was conducted to assess the effectiveness and safety of ranolazine. Patients eligible for enrolment had a baseline assessment between one and fourteen days after initiating ranolazine for the first time and a follow-up visit three months later. The primary endpoints comprised the weekly frequency of angina attacks, total adverse events, and ranolazine discontinuation rate. The secondary endpoints included the use of short-acting nitrates, changes on the Canadian Cardiovascular Society (CCS) angina classification score and quality of life scale score (QoL). Results: In total, 1101 patients were enrolled at 214 sites. Mean weekly angina attacks were reduced from 3.6 \u00b1 2.9 to 0.4 \u00b1 0.9 (p &lt; 0.0001) and the mean weekly consumption of short-acting nitrates decreased by 1.7 \u00b1 2.2 (p &lt; 0.0001). CCS class and QoL were also improved (p &lt; 0.0001). Adverse events were reported by 11 (1%) patients in total, while 2 of them (0.2%) were characterised as serious. Treatment was discontinued for various reasons in 23 patients (2.1%) after the follow-up period. Ranolazine treatment was equally effective in all subgroups tested, with larger benefits observed in patients with more frequent angina and CCS angina class III and IV. Up-titration of ranolazine during the study improved the outcomes. Conclusions: Ranolazine was well tolerated and effectively reduced angina attacks, with simultaneous improvement of the CCS class and QoL score in patients with stable angina.<\/jats:p>","DOI":"10.3390\/jcm13061672","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T04:47:05Z","timestamp":1710478025000},"page":"1672","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Christoforos","family":"Olympios","sequence":"first","affiliation":[{"name":"Cardiology Department, Thriassio General Hospital of Elefsina, 196 00 Magoula, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-5451","authenticated-orcid":false,"given":"Panagiotis","family":"Stafylas","sequence":"additional","affiliation":[{"name":"Healthink, Pylaia, 570 01 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkiviadis","family":"Dermitzakis","sequence":"additional","affiliation":[{"name":"Cardiology Department, Venizelio General Hospital, 714 09 Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Efthimiadis","sequence":"additional","affiliation":[{"name":"Bioclinic Thessaloniki, 546 22 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Gardikiotis","sequence":"additional","affiliation":[{"name":"Cardiology Department, 417 NIMTS Veterans\u2019 Fund Hospital of Athens, 115 21 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Kakouros","sequence":"additional","affiliation":[{"name":"Cardiology Department, Sismanogleio General Hospital, 151 26 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Lampropoulos","sequence":"additional","affiliation":[{"name":"Cardiology Department, Mamatseio General Hospital, 501 00 Kozani, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Barbetseas","sequence":"additional","affiliation":[{"name":"Cardiology Department, General Hospital \u201cLAIKO\u201d, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Sourgounis","sequence":"additional","affiliation":[{"name":"Cardiology Department, 424 General Military Hospital, 564 29 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of RANGER Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1056\/NEJMcp042317","article-title":"Chronic stable angina","volume":"352","author":"Abrams","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_3","first-page":"1593","article-title":"Insight to the Pathophysiology of Stable Angina Pectoris","volume":"19","author":"Tousoulis","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/heart.87.2.140","article-title":"Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population","volume":"87","author":"Brorsson","year":"2002","journal-title":"Heart"},{"key":"ref_5","unstructured":"National Institute for Health and Care Excellence (2023, December 04). Stable Angina: Management. Clinical Guideline CG126; NICE, Manchester, UK, 2016. Available online: https:\/\/www.nice.org.uk\/guidance\/cg126\/resources\/stable-angina-management-pdf-35109453262021."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejim.2021.08.003","article-title":"State of the art approach to managing angina and ischemia: Tailoring treatment to the evidence","volume":"92","author":"Manolis","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"ref_7","unstructured":"European Medicines Agency (2023, December 04). Ranexa: Summary of Product Characteristics (EMEA\/H\/C\/000805-N\/0068). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ranexa-epar-product-information_en.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2009.01.037","article-title":"Efficacy of Ranolazine in Patients with Chronic Angina. Observations From the Randomized, Double-Blind, Placebo-Controlled MERLIN-TIMI (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial","volume":"53","author":"Wilson","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/2047487312450133","article-title":"Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: Analysis from the Combination Assessment of Ranolazine in Stable Angina (CARISA) randomized trial","volume":"19","author":"Lee","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: Results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/2047487314533217","article-title":"Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis","volume":"22","author":"Belsey","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00508-019-1481-x","article-title":"Ranolazine: Impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria\u2014The ARETHA AT study","volume":"131","author":"Zweiker","year":"2019","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of Ranolazine with Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients with Severe Chronic Angina: A Randomized Controlled Trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2015.10.180","article-title":"Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR)","volume":"205","author":"Alexopoulos","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal Efficacy of Ranolazine When Added to Treatment with Amlodipine","volume":"48","author":"Stone","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.108.798009","article-title":"Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: Results from the MERLIN-TIMI 36 randomized trial","volume":"1","author":"Arnold","year":"2008","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJM200006223422511","article-title":"Randomized trials or observational tribulations?","volume":"342","author":"Pocock","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1076-7460.2007.07119.x","article-title":"Safety and Efficacy of Extended-Release Ranolazine in Patients Aged 70 Years or Older with Chronic Stable Angina Pectoris","volume":"16","author":"Rich","year":"2007","journal-title":"Am. J. Geriatr. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cacciatore, S., Spadafora, L., Bernardi, M., Galli, M., Betti, M., Perone, F., Nicolaio, G., Marzetti, E., Martone, A.M., and Landi, F. (2023). Management of Coronary Artery Disease in Older Adults: Recent Advances and Gaps in Evidence. J. Clin. Med., 12.","DOI":"10.3390\/jcm12165233"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4172\/2155-9880.1000412","article-title":"Application of Ranolazine in Stable Angina Pectoris Therapy (ARETHA): Real-World Data from an Observational Study","volume":"6","author":"Diedrichs","year":"2015","journal-title":"J. Clin. Exp. Cardiolog."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40256-013-0038-z","article-title":"Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris","volume":"13","author":"Ling","year":"2013","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"141.e1","DOI":"10.1016\/j.carrev.2011.06.001","article-title":"Ranolazine for the treatment of refractory angina in a veterans population","volume":"13","author":"Greene","year":"2012","journal-title":"Cardiovasc. Revascularization Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2013.08.131","article-title":"Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis","volume":"169","author":"Savarese","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7861\/clinmedicine.13-1-63","article-title":"Pharmacological treatment of chronic stable angina pectoris","volume":"13","author":"Tarkin","year":"2013","journal-title":"Clin. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"De Luca, L., Temporelli, P.L., Lucci, D., Colivicchi, F., Calabr\u00f2, P., Riccio, C., Amico, A., Mascia, F., Proia, E., and Di Lenarda, A. (2018). Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199770"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamacardio.2018.2849","article-title":"The Evolution of Patient-Reported Outcomes in Clinical Trials and Management of Patients with Coronary Artery Disease: 20 Years with the Seattle Angina Questionnaire","volume":"3","author":"Spertus","year":"2018","journal-title":"JAMA Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1672\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:13:35Z","timestamp":1760105615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13061672"],"URL":"https:\/\/doi.org\/10.3390\/jcm13061672","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}